David Berman
- Pathologist and Clinician Scientist, Kingston General Hospital Research Institute
- Director, Queen's Cancer Research Institute
- Professor, Department of Pathology & Molecular Medicine, Queen’s
Pathology, prostate cancer, bladder cancer, cancer biomarkers
David M Berman pursued MD and PhD degrees at U.T. Southwestern (Texas), where he cloned the cDNA for the enzyme 5-alpha reductase and elucidated its role in prostate development. He then performed anatomic pathology and subspecialty training in urologic pathology at Johns Hopkins University, followed by a postdoctoral fellowship in Molecular Biology and Genetics. He ran a research laboratory at Johns Hopkins for nine years prior to moving the laboratory to Queen’s University in Kingston Ontario. His research focuses on high impact biomarkers in prostate and bladder cancer. He performs diagnostic surgical pathology one week per month and devotes the rest of his professional efforts to research.
- Md, PhD U.T. Southwestern (Texas)
Dr. Berman is leading a team of scientists across Canada who are studying a large number of genes that will form the foundation of new tests for prostate cancer. The group will study prostate cancer samples from two patient groups in Kingston and Montreal, looking for specific molecular features, such as the modification, gain, or loss of particular genes. The goal of this work, funded by Movember and Prostate Cancer Canada, is to develop new and better tests that help clarify decision-making for men newly diagnosed with prostate cancer, and improve their quality of life.
